Genetically elevated circulating levels of osteoprotegerin are associated with a reduced risk of developing type 2 diabetes, according to findings from a drug-target Mendelian randomization study. The research provides genetic evidence that genetically predicted higher osteoprotegerin levels are associated with lower type 2 diabetes risk. By leveraging human genetic variation within an established analytical framework, the investigators assessed the causal effect of circulating osteoprotegerin on type 2 diabetes risk and the mediating effect of pancreatic beta-cell function.
The scientific investigation was motivated by previous observational evidence concerning denosumab, a therapeutic agent that operates through biological pathways partially analogous to the endogenous osteoprotegerin protein. Prior clinical observations indicated that treatment with denosumab might correlate with a reduced incidence of type 2 diabetes among patients. Because denosumab shares functional characteristics with osteoprotegerin in its biological pathway, these observations prompted questions regarding whether directly modulating the osteoprotegerin pathway could influence metabolic health. To address this question rigorously, the researchers sought to assess the causal relationship between circulating osteoprotegerin levels, broader glycemic traits, and overall diabetes risk.
To examine these potential relationships, the research team conducted a drug-target Mendelian randomization analysis, a methodological approach designed to evaluate causal effects using genetic variants as instrumental variables. The analytical workflow was structured across distinct stages to maintain methodological rigor. Specifically, the authors conducted genetic instrument discovery, exposure effect estimation, and outcome association testing using separate summary-level data sources. This separation ensured that the identification of genetic proxies for circulating osteoprotegerin remained independent of the datasets used to assess associations with diabetes outcomes and metabolic parameters.
The primary Mendelian randomization analysis revealed that genetically elevated circulating osteoprotegerin was associated with a statistically significant reduction in the risk of type 2 diabetes. The authors reported an odds ratio of 0.912, accompanied by a 95 percent confidence interval spanning from 0.857 to 0.972 and a significance value of P = 0.004.
In addition to examining overall diabetes diagnosis, the investigators performed secondary analyses to assess how circulating osteoprotegerin concentrations relate to continuous glycemic traits. Within these secondary investigations, higher osteoprotegerin levels demonstrated a nominal association with reduced glycated hemoglobin levels, commonly referred to as HbA1c. The calculated effect estimate showed a beta coefficient of -0.027, with a 95 percent confidence interval ranging from -0.050 to -0.004 and a P value of 0.023. The authors characterized this finding as an exploratory secondary observation suggesting that osteoprotegerin pathway activity may also influence long-term blood glucose regulation.
To elucidate the potential biological pathways mediating this protective relationship, the researchers conducted a formal mediation analysis focusing on pancreatic beta-cell function. Beta-cell performance was quantitatively assessed using the homeostasis model assessment of beta-cell function. The resulting mediation modeling suggested that enhanced pancreatic beta-cell function may partly mediate the protective association between elevated osteoprotegerin levels and reduced type 2 diabetes risk.
Based on these findings, the study authors concluded that genetic evidence supports an inverse relationship between genetically predicted osteoprotegerin concentrations and type 2 diabetes risk, driven in part by improvements in pancreatic beta-cell function. The authors noted that these results support further experimental and clinical investigation into pharmacological modulation of the osteoprotegerin pathway for type 2 diabetes prevention.
Subject of Research: Causal effect of circulating osteoprotegerin levels on type 2 diabetes risk and glycemic traits
Article Title: Osteoprotegerin lowers type 2 diabetes risk: insights from drug-target Mendelian randomization and mediation analysis
Article References: Ha, H., Lee, W. V., An, Y., Kim, I.-W., & Oh, J. M. (2026). Osteoprotegerin lowers type 2 diabetes risk: insights from drug-target Mendelian randomization and mediation analysis. Diabetology & Metabolic Syndrome. https://doi.org/10.1186/s13098-026-02310-0
Image Credits: AI Generated
DOI: 10.1186/s13098-026-02310-0
Keywords: osteoprotegerin, type 2 diabetes, Mendelian randomization, beta-cell function, glycemic traits, denosumab, HbA1c, metabolic genetics, lowers, type, diabetes, risk